Trial Profile
Clinical Study of Tegafur and Apatinib Combination to Second Line Treating Advanced Pancreatic Cancer
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 May 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Tegafur (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 04 May 2018 New trial record